Results 211 to 220 of about 168,641 (363)

Amino-Terminal Pro–C-Type Natriuretic Peptide in Heart Failure [PDF]

, 2003
S. Wright, Timothy C. R. Prickett, Robert N. Doughty, Chris Frampton, Greg Gamble, Timothy G. Yandle, Norman Sharpe, Mark Richards   +7 more
openalex   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial Integrity

HYPERTENSION, 2017
K. Nakao, K. Kuwahara, T. Nishikimi, Y. Nakagawa, Hideyuki Kinoshita, Takeya Minami, Yoshihiro Kuwabara, Chinatsu Yamada, Yuko Yamada, T. Tokudome, Chiaki Nagai-Okatani, N. Minamino, Y. Nakao, S. Yasuno, K. Ueshima, Masakatsu Sone, Takeshi Kimura, K. Kangawa, K. Nakao   +18 more
semanticscholar   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP. [PDF]

Br J Clin Pharmacol, 2022
Breinholt VM, Mygind PH, Christoffersen ED, Zhang Y, Ota S, Will Charlton R, Viuff D.   +6 more
europepmc   +1 more source

Functional Analysis of Genomic DNA, cDNA, and Nucleotide Sequence of the Mature C-Type Natriuretic Peptide Gene in Vascular Cells [PDF]

, 2004
Jaroslav Pelisek, Andreas Kuehnl, Pierre H. Rolland, Choukri Mekkaoui, Alexandra Fuchs, Greg F. Walker, Manfred Ogris, Ernst Wagner, Sigrid Nikol   +8 more
openalex   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

C-type natriuretic peptide facilitates autonomic Ca²⁺ entry in growth plate chondrocytes for stimulating bone growth. [PDF]

Elife, 2022
Miyazaki Y, Ichimura A, Kitayama R, Okamoto N, Yasue T, Liu F, Kawabe T, Nagatomo H, Ueda Y, Yamauchi I, Hakata T, Nakao K, Kakizawa S, Nishi M, Mori Y, Akiyama H, Nakao K, Takeshima H.   +17 more
europepmc   +1 more source

cAMP inhibits natriuretic peptide receptor-B activity and increases C-type natriuretic peptide in FRTL-5 rat thyroid cells [PDF]

, 2004
D. F. Sellitti, Enrico Fuini Puggina, Cláudia Jacques Lagranha, SQ Doi   +3 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source